Figure 6.

Ganaxolone (GANAX) and alphaxolone (ALPHAX) differentially mitigate tetramethylenedisulfotetramine (TETS)-triggered SCO patterns. Upper panels in (A–D) show the experimental protocol for recording SCO during baseline and phases I and II postaddition of TETS (3.0 µM) and subsequent addition of either 0.1–3.0 µM GANAX or 0.1–3.0 µM ALPHAX, respectively. Only phase II responses were analyzed in this study. A–D, Total amplitude (red bars), high amplitude SCO events (blue bars) and low amplitude SCO events (green bars) are normalize to Vehicle control (0.01% DMSO) and statistically compared with Vehicle (*) or TETS (^#) using ANOVA with Tukey post hoc correction. Mean ± SEM (n = 9–15 wells measured on 3 independent culture days). * ^#p < .05; **^,##p < .01; ^***,###p < .001. Summary statistics are reported in Table 2.